Clinical Trial Search

Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants

Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05

Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate

Primary: Contamination of Disposable Isolation Gown and Gloves With Methicillin-resistant Staphylococcus Aureus or Multi-drug-resistant Acinetobacter Baumannii — 20.5; 17.2…

Primary: MRSA Transmission — 0.20; 0.02; 0.11; 0.01 Proportion of swabs positive for MRSA

Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants

Primary: Number of Environmentally-implicated Healthcare-Associated Infections (eiHAIs) Associated With the Additional Use of a PX-UV Disinfection Compared to Standard Terminal…

Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026

Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants

Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21

Primary: Hospital Transfers Due to Infection — 1243; 1780 Transfers — p=<0.001

Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants

Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17

Primary: Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization — 2; 3 Participants

Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers

Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants

Primary: Main Outcome: Patients With Nosocomial MRSA Clinical Cultures — 0.92; 0.75; 0.63 hazard ratio — p=0.01

Primary: Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit — 21.2; 20.9; 19.1; 21.6 percentage of visits prescribed an abx — p=0.35

Primary: Acquisition of Methicillin-resistant Staph Aureus (MRSA) Colonization or Infection — 9; 10 participants — p=>0.05

Primary: Incidence of Skin and Soft Tissue Infection (SSTI) — 303; 439; 461 participants

Primary: Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days — 5.44; 3.1 CLABSI per 1000 at-risk days.

Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants

Primary: The Presence of MRSA on Repeated Swabs to Assess the Efficacy of These Medications on Clearing MRSA Colonization — 12; 14; 0 Participants

Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356

Primary: Number of Participants With Postoperative Healthcare Acquired Infections — 108; 116 Participants

Primary: Number of Patients With Adverse Events During and After FMT — 1 Participants

Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants

Primary: Total Bacterial Contamination of Healthcare Worker Uniform With Antimicrobial Properties Compared to Standard Healthcare Worker Uniform After an 8-hour Workday. — 41…

Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…

Primary: Vancomycin-Resistant Enterococcus (VRE) Colonization — 0; 0; 30; 33 participants with VRE colonization — p=0.671